What are JAK inhibitors?
Janus kinases (JAKs) are proteins that can be found inside certain cells, including stem cells located in the bone marrow.

You are about to leave a GSK website
You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content.
OJJAARA is a type of medicine called a Janus kinase inhibitor (JAK inhibitor).
Janus kinases (JAKs) are proteins that can be found inside certain cells, including stem cells located in the bone marrow.
In myelofibrosis, the DNA in normal bone marrow cells changes. This DNA mutation may cause JAKs to become overactive. As myelofibrosis progresses, there is more Janus kinase overactivity. Researchers believe these abnormal bone marrow stem cells cause inflammation that may lead to a buildup of scar tissue inside the bone marrow. The formation of this scar tissue, known as fibrosis, replaces some of the normal bone marrow, leading to a decreased production of normal blood cells.
OJJAARA is believed to work by binding to, and inhibiting, the activity of overactive JAKs.
In addition to inhibiting Janus kinase proteins, OJJAARA inhibits a signal from another protein called Activin A receptor type 1, or ACVR1, in the liver cells. This can result in an increase in your number of red blood cells.
You'll receive access to information and resources about OJJAARA that may support you on your journey.
OJJAARA is the first and only FDA-approved treatment specifically for adults with certain types of myelofibrosis who have anemia.
Learn about getting started on OJJAARA, including dosing information.